A fixed-dose combination of ledipasvir and sofosbuvir ± ribavirin for treatment of hepatitis C infection: a systematic review and meta-analysis

[1]  M. Manns,et al.  Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. , 2017, The Lancet. Infectious diseases.

[2]  Yuehong Chen,et al.  Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[3]  T. Asselah,et al.  Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection , 2016, Hepatology.

[4]  Da-Zhi Zhang,et al.  Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis , 2016, Digestive Diseases and Sciences.

[5]  Ju-Hyun Kim,et al.  A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus , 2016, Hepatology International.

[6]  L. Rostaing,et al.  Efficacy and Safety of Sofosbuvir‐Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  T. Asselah,et al.  Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. , 2016, The Lancet. Infectious diseases.

[8]  G. Lauer,et al.  The Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of a Nosocomial Outbreak of HCV in Patients with Significant Cardiovascular Disease , 2016, Antiviral therapy.

[9]  C. Stedman,et al.  Once daily ledipasvir/sofosbuvir fixed‐dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  H. Masur,et al.  Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  M. Stepanova,et al.  The impact of ledipasvir/sofosbuvir on patient‐reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[12]  M. Sulkowski,et al.  Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. , 2015, Gastroenterology clinics of North America.

[13]  M. Nguyen,et al.  Current Treatment Options in Patients with Hepatitis C Virus Genotype 6. , 2015, Gastroenterology clinics of North America.

[14]  M. Proschan,et al.  High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study , 2015, Hepatology International.

[15]  M. Proschan,et al.  Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. , 2015, Annals of internal medicine.

[16]  M. Pedrosa,et al.  Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV) , 2015, Advances in Therapy.

[17]  C. Stedman,et al.  Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. , 2015, Gastroenterology.

[18]  E. Schiff,et al.  Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. , 2015, Gastroenterology.

[19]  M. Polis,et al.  Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. , 2015, The Lancet. Infectious diseases.

[20]  P. Sax,et al.  Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. , 2015, The New England journal of medicine.

[21]  P. Marcellin,et al.  Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. , 2015, Journal of hepatology.

[22]  T. Ide,et al.  Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. , 2015, The Lancet. Infectious diseases.

[23]  P. Pang,et al.  Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens , 2015, Hepatology.

[24]  P. Marcellin,et al.  Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials , 2015, Hepatology.

[25]  M. Stepanova,et al.  Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States , 2015, Hepatology.

[26]  Brad J. Wood,et al.  Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. , 2015, JAMA.

[27]  Brad J. Wood,et al.  Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study , 2015, The Lancet.

[28]  Jagpreet Chhatwal,et al.  Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States , 2015, Annals of Internal Medicine.

[29]  A. Fauci,et al.  Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse , 2014, Annals of Internal Medicine.

[30]  H. Razavi,et al.  Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.

[31]  A. Flaxman,et al.  Global Distribution and Prevalence of Hepatitis C Virus Genotypes , 2014, Hepatology.

[32]  Robert Herring,et al.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[33]  Stefan Zeuzem,et al.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[34]  Sanjeev Arora,et al.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[35]  J. Ward,et al.  Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 , 2014, Annals of Internal Medicine.

[36]  C. Stedman,et al.  Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. , 2014, Gastroenterology.

[37]  H. Mo,et al.  Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial , 2014, The Lancet.

[38]  J. Pawlotsky.  NS5A inhibitors in the treatment of hepatitis C. , 2013, Journal of hepatology.

[39]  J. Murray,et al.  Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. , 2013, Gastroenterology.

[40]  S. Saab,et al.  Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[41]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[42]  A. Larson,et al.  Adult liver transplantation in the USA , 2011, Current opinion in gastroenterology.

[43]  David B. Goldstein,et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.

[44]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[45]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[46]  Thomas A Trikalinos,et al.  The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey , 2007, Canadian Medical Association Journal.

[47]  Christopher H Schmid,et al.  In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. , 2005, Journal of clinical epidemiology.

[48]  C. Beckwith,et al.  Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy : a randomised , double-blind , phase 2 trial ( SIRIUS ) , 2015 .

[49]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.